Accelerated atherosclerosis in systemic lupus erythematosus: Implications for patient management

Current Opinion in Rheumatology

Volumn 13, Issue 5, 2001, Pages 341-344

  Salmon, Jane E ^a,b   Roman, Mary J ^a  

^a WEILL CORNELL MEDICAL COLLEGE   (United States)

^b HOSPITAL FOR SPECIAL SURGERY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CORTICOSTEROID;

ATHEROSCLEROSIS; CARDIOVASCULAR DISEASE; CHRONIC INFLAMMATION; CORONARY ARTERY DISEASE; HUMAN; PATIENT CARE; PRIORITY JOURNAL; REVIEW; RISK FACTOR; SYSTEMIC LUPUS ERYTHEMATOSUS;

ADULT; ARTERIOSCLEROSIS; FEMALE; HUMANS; LUPUS ERYTHEMATOSUS, SYSTEMIC; MIDDLE AGED; RISK FACTORS;

EID: 0034817394     PISSN: 10408711     EISSN: None     Source Type: Journal    
DOI: 10.1097/00002281-200109000-00001     Document Type: Review

References (33)

1. Coronary arterial disease in systemic lupus erythematosus: Quantification of degrees of narrowing in 22 necropsy patients (21 women) aged 16 to 37 years
2. Prevalence and mortality rates of systemic lupus erythematousus and causes of death in SLE patients in Finland
3. Outcome in SLE: A prospective study of patients from a defined population
4. Risk factors for coronary artery disease in patients with SLE
5. A multicenter study of outcome in SLE. II. Causes of death
6. Causes of death in systemic lupus erythematosus: Long-term followup of an inception cohort
7. Mortality studies in SLE. Results from a single center. I. Causes of death
8. Premature morbidity from cardiovascular and cerebrovascular diseases in women with systemic lupus erythematosus
9. Epidemiology of cardiovascular disease in systemic lupus erythematosus
10. Detection of coronary artery disease and the role of traditional risk factors in the Hopkins Lupus Cohort
11. The bimodal mortality pattern of SLE
12. The heart in SLE and the changes induced in it by corticosteroid therapy. A study of 36 necropsy patients
13. Age-specific incidence rates of myocardial infarction and angina in women with systemic lupus erythematosus: Comparison with the Framingham study
14. Coronary artery disease risk factors in the Johns Hopkins SLE cohort: Prevalence, recognition by patients, and preventive practices
15. Prevalence and risk factors of carotid plaque in women with systemic lupus erythematosus
16. Myocardial infarction and stroke in SLE: Markedly increased incidence after controlling for risk factors
17. Ultrasonographically assessed carotid morphology and the risk of coronary heart disease
18. Subclinical disease as an independent risk factor for cardiovascular disease
19. Atherosclerotic changes in the carotid artery bulb as measured by B-mode ultrasound are associated with the extent of coronary atherosclerosis
20. Prevalence and relation to risk factors of carotid atherosclerosis and left ventricular hypertrophy in systemic lupus erythematosus and antiphospholipid antibody syndrome
21. Atherosclerosis-an inflammatory disease
22. Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men
23. Circulating adhesion molecules VCAM-1, ICAM-1, and E-selectin in carotid atherosclerosis and incident coronary heart disease cases: The Atherosclerosis Risk in Communities (ARIC) Study
24. Plasma concentration of soluble intercellular adhesion molecule 1 and risks of future myocardial infarction in apparently healthy men
25. Pathology and pathogenesis of vascular injury in systemic lupus erythematosus
26. Guide to preventive cardiology for women
27. Detection and modification of risk factors for coronary artery disease in patients with systemic lupus erythematosus: A quality improvement study
28. Diabetes and cardiovascular disease: A statement for healthcare professionals from the American Heart Association
29. Long-term effects of pravastatin on plasma concentration of C-reactive protein
30. Statin therapy, lipid levels, C-reactive protein and the survival of patients with angiographically severe coronary artery disease
31. Cholesterol lowering effect of hydroxychloroquine in patients with rheumatic disease: Reversal of deleterious effects on lipids
32. The cholesterol lowering effect of antimalarial drugs is enhanced in patients taking corticosteroid drugs
33. AHA Conference Proceedings. Prevention conference V: Beyond secondary prevention: Identifying the high-risk patient for primary prevention: Executive summary